Compare CRDL & BHST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRDL | BHST |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | Canada | Canada |
| Employees | N/A | 87 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.3M | 104.2M |
| IPO Year | 2017 | N/A |
| Metric | CRDL | BHST |
|---|---|---|
| Price | $1.03 | $4.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $9.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 365.5K | 16.4K |
| Earning Date | 05-13-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $116.40 |
| Revenue Next Year | N/A | $55.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.77 | $4.10 |
| 52 Week High | $1.59 | $12.80 |
| Indicator | CRDL | BHST |
|---|---|---|
| Relative Strength Index (RSI) | 51.67 | 47.33 |
| Support Level | $0.95 | $4.19 |
| Resistance Level | $1.09 | $4.96 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 63.00 | 40.54 |
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.